News Articles and Montana BioScience Alliance Newsletters
Golden Helix, Inc. announced that it has received the certification for ISO 13485:2016 from TÜV SÜD. ISO 13485:2016 is an international standard that specifies requirements for a quality management system (QMS) for organizations involved in the design, development, production, and servicing of medical devices. It is specifically tailored to the medical device industry and is recognized globally as a benchmark for ensuring the quality and safety of medical devices.
The National Institutes of Health recently awarded a Montana State University doctoral student a prestigious Graduate Partnership Program Fellowship. Through the fellowship, Jonathan Shikany, a second-year doctoral student in MSU’s Department of Chemical and Biological Engineering in the Norm Asbjornson College of Engineering, will receive funding for tuition and living expenses as he completes his degree, as well as funding to cover research-related expenses.
The grant money will launch the Center for Integrated Biomedical and Rural Health Research or CIB-RHR, expanding the research enterprise over the next five years, with the ultimate hope of bringing healthcare improvements to the state.
Sana Health and Lutroo Imaging emerged victorious among 70 competing startups and early-stage companies, securing the top honors at the inaugural American Academy of Pain Medicine (AAPM) and MIT Hacking Medicine Innovation Challenge presented by Abbott. Their success grants them the coveted opportunity to collaborate with Michael Hooten, M.D., president of AAPM and professor of Anesthesiology at the Mayo Clinic.
The Montana Innovation Partnership at Montana State University’s TechLink Center will host “Innovate Here,” a one-day virtual conference March 7 focused on key technology industries in Montana, such as bioscience, photonics and quantum technologies.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.
The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.
The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.
Drug makers have been racing at a breakneck pace to develop respiratory syncytial virus (RSV) vaccines this year. On May 3, the U.S. Food and Drug Administration (FDA) announced it has approved Arexvy, the first-ever RSV vaccine for individuals 60 and over.